A. Oral azacitidine was compared to decitabine as maintenance therapy B. Oral azacitidine demonstrated an improved overall survival rate when used as maintenance therapy C. Oral azacitidine demonstrated a reduced quality of life at all time points compared to the control arm D. Oral azacitidine patients received a median of 3 consolidation cycles prior to randomization E. Unsure

A. Gilteritinib 80 mg by mouth once daily B. Sorafenib 400 mg by mouth BID C. Midostaurin 50 mg by mouth once daily D. Ponatinib 45 mg by mouth once daily E. Unsure

A. Sorafenib causes a very high rate of nausea/vomiting and should be taken with anti-emetic prophylaxis B. Sorafenib may cause dermatologic reactions C. Midostaurin causes a high rate of QTc prolongation and requires weekly EKG monitoring D. Midostaurin should be taken on an empty stomach, once daily in the morning E. Unsure

A. IV azacitidine may be substituted with oral azacitidine at twice the dose B. Oral azacitidine leads to a lower rate of hypomethylation compared to IV azacytidine C. Oral azacitidine has not improved OS rates as maintenance therapy, but IV azacitidine has improved overall survival D. Oral azacitidine has equivalent bioavailability and hypomethylation capacity as IV azacitidine E. Unsure

A. Midostaurin 50 mg BID + voriconazole 200 mg BID B. Ponatinib 15 mg once daily + fluconazole 200 mg once daily C. Sorafenib 400 mg BID + posaconazole 300 mg once daily D. Gilteritinib 120 mg once daily + isavuconazole 372 mg once daily E. Unsure